In conclusion, the present study has demonstrated that expression of SnoN protein in rats with early DN is downregulated by UPP and that the proteasome inhibitor, MG132, can reduce degradation of SnoN, thus inhibiting activation of the TGF-β pathway and conferring a therapeutical effect for DN in vivo. Here, TGFB1 is linked to liver dysplastic nodule.